The immunological synapse for B-cell memory: The role of the ICOS and its ligand for the longevity of humoral immunity

Current Opinion in Allergy and Clinical Immunology

Volumn 3, Issue 6, 2003, Pages 409-419

  Grimbacher, Bodo ^a   Warnatz, Klaus ^a   Peter, Hans Hartmut ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Humoral immunity; ICOS; Immunoglobulin; Memory B cells

Indexed keywords

B7 ANTIGEN; CD28 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; CD86 ANTIGEN; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; ICOS ANTIGEN; IMMUNOGLOBULIN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN M; INTERFERON REGULATORY FACTOR 4; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; STAT1 PROTEIN; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR AP 2; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR PU 1; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG; INDUCIBLE T CELL CO STIMULATOR; INDUCIBLE T-CELL CO-STIMULATOR; T LYMPHOCYTE ANTIGEN;

ALLERGY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ASTHMA; AUTOIMMUNITY; B LYMPHOCYTE; CHROMOSOME 2Q; COMMON VARIABLE IMMUNODEFICIENCY; CYTOKINE RELEASE; GENE EXPRESSION REGULATION; HISTOCOMPATIBILITY; HUMORAL IMMUNITY; INFLUENZA VIRUS; LEISHMANIA; LISTERIA MONOCYTOGENES; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MEMORY CELL; MOUSE; NATURAL KILLER CELL; NONHUMAN; PARASITOSIS; PRIORITY JOURNAL; REVIEW; SCHISTOSOMA MANSONI; SIGNAL TRANSDUCTION; TOXOPLASMA GONDII; TRANSCRIPTION INITIATION SITE; TUMOR IMMUNITY; VESICULAR STOMATITIS VIRUS; VIRUS INFECTION; ANIMAL; GENETICS; HELPER CELL; HUMAN; IMMUNITY; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; INFECTION; NEOPLASM; PHYSIOLOGY;

ANIMALS; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; AUTOIMMUNITY; B-LYMPHOCYTES; HUMANS; IMMUNITY; IMMUNOLOGIC MEMORY; INFECTION; NEOPLASMS; T-LYMPHOCYTES, HELPER-INDUCER; TRANSPLANTATION IMMUNOLOGY;

EID: 3543076517     PISSN: 15284050     EISSN: None     Source Type: Journal    
DOI: 10.1097/00130832-200312000-00001     Document Type: Review

References (67)

1. Carreno BM, Collins M. The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Annu Rev Immunol 2002; 20:29-53. The most complete review on immunoglobulin-like costimulatory T cell receptors and their B7 family of ligands. The review nicely addresses clinical and therapeutical implications by blocking these pathways.
2. Sharp AH, Freeman JG. The B7-CD28 superfamily. Nat Rev Immunol 2002; 2:116-126. Very comprehensive review of the current knowledge on new members of the B7 and CD28 families, their costimulatory pathways and regulatory potential also in view of therapeutic interventions.
3. Greenwald RJ, Latchman YE, Sharpe AH. Negative co-receptors on lymphocytes. Curr Opin Immunol 2002; 14:391-396.
4. Okazaki T, Iwai Y, Honjo T. New regulatory co-receptors: inducible costimulator and PD-1. Curr Opin Immunol 2002; 14:779-782.
5. Liang L, Sha WC. The right place at the right time: novel B7 family members regulate effector T cell responses. Curr Opin Immunol 2002; 14:384-390.
6. Bennett F, Luxenberg D, Ling V, et al. Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: attenuation of ICOS, IL-4, and IL-21; but not CD28, IL-7, and IL-15 responses. J Immunol 2003; 170:711-718.
7. Andersen ADH, Lange M, Lillevang ST. Allelic variation of the inducible costimulator (ICOS) gene: detection of polymorphisms, analysis of the promoter region, and extended haplotype estimation. Tissue Antigens 2003; 61:276-285. This study screened for genetic polymorphisms within the ICOS gene and addressed their potential role in gene expression.
8. Haimila KE, Partanen JA, Holopainen PM. Genetic polymorphism of the human ICOS gene. Immunogenetics 2002; 53:1028-1032.
9. Feito MJ, Vaschetto R, Criado G, et al. Mechanisms of H4/ICOS costimulation: effects on proximal TCR signals and MAP kinase pathways. Eur J Immunol 2003; 33:204-214. Demonstrates that ICOS cross-linking strongly enhances CD3 mediated tyrosin phosphorylation of ZAP-70, ζ, Vav and ERK, JNK and p38 kinase activation.
10. Rudd CE, Schneider H. Unifying concepts in CD28, ICOS and CTLA4 coreceptor signaling. Nat Rev Immunol 2003; 3:544-556. Important and extensive review of current knowledge on signaling pathways engaged by the three co-receptors of the CD28 receptor family.
11. Frauwirth KA, Thompson CB. Activation and inhibition of lymphocytes by costimulation. J Clin Invest 2002; 109:295-299. This review summarizes the knowledge of downstream-signaling events induced after T cell costimulation.
12. Coyle AJ, Lehar S, Lloyd C, et al. The CD28-related molecule ICOS is required for effective T cell-dependent immune responses. Immunity 2000; 13:95-105.
13. Hutloff A, Dittrich AM, Beier KC, et al. ICOS is an inducible T-cell costimulator structurally and functionally related to CD28. Nature 1999; 397:263-266.
14. Yoshinaga SK, Whoriskey JS, Khares SD, et al. T cell co-stimulation through B7RP-1 and ICOS. Nature 1999; 402:827-832.
15. Harada Y, Ohgai D, Watanabe R, et al. A single amino acid alteration in cytoplasmic domain determines IL-2 promoter activation by ligation of CD28 but not inducible costimulator (ICOS). J Exp Med 2003; 197:257-262.
16. + T cells. Increased IL-4, IL-10 and IFN-γ production in ICOS costimulated T cells is associated with strong activation of the PI3-K-PDK1-Akt/PKB pathway. In addition the MAPK family kinases are activated in different ways by ICOS and CD28. Interestingly, the natural skewing towards Th2 cytokine responses in Balb/c versus Th1 dominated cytokine responses in C57BI/6 mice is associated with a much higher expression of ICOS on Balb/c versus C57BI/6 CD4+ T cells.
17. -/- T cells (transgenic for a specific TCR) expressed reduced levels of ICOS, GATA-3, STAT6 and phosphorylated STAT6 when activated by antigen-presenting B cells.
18. Riley JL, Mao M, Kobayashi S, et al. Modulation of TCR-induced transcriptional profiles by ligation of CD28, ICOS, and CTLA-4 receptors. Proc Natl Acad Sci U S A 2002; 99:11790-11795. This paper investigated the differential gene expression of T cells after various costimulatory signals by gene chip analysis. Interestingly, costimulation through CD28 regulates only few genes differently than costimulation through ICOS.
19. Nurieva RI, Duong J, Kishikawa H, et al. Transcriptional regulation of Th2 differentiation by inducible costimulator. Immunity 2003; 18:801-811. Provides additional insight into the downstream signaling cascade following ICOS ligation.
20. McAdam AJ, Greenwald RJ, Levin MA, et al. ICOS is critical for CD40-mediated antibody class switching. Nature 2001; 409:102-105.
21. Liang L, Porter EM, Sha WC. Constitutive expression of the B7h ligand for inducible costimulator on naive B cells is extinguished after activation by distinct B cell receptor and IL4-receptor mediated pathways and can be rescued by CD40 signaling. J Exp Med 2002; 196:97-108. The data suggest that the CD40: CD40-L signaling pathway regulates B7h expression on activated B cells and may control whether antigen-activated B cells can express B7h and costimulate cognate antigen-activated T cells through ICOS.
22. Smith KM, Brewer JM, Webb P, et al. Inducible costimulatory molecule-B7-related protein 1 interactions are important for the clonal expansion and B cell helper functions of naive, Th1, and Th2 T cells. J Immunol 2003; 170:2310-2315. This study shows that ICOS is important for the initial clonal expansion of primary and primed Th1 and Th2 cells in response to immunization. Furthermore, although it has no effect on the migration of T cells into B cell follicles, it is essential for their ability to support B cell responses.
23. Ling V, Wu PW, Finnerty HF, et al. Cutting edge: identification of GL50, a novel B7-like protein that functionally binds to ICOS receptor. J Immunol 2000; 164:1653-1657.
24. Wang S, Zhu G, Chapoval AI, et al. Costimulation of T cells by B7-H2, a B7-like molecule that binds ICOS. Blood 2000; 96:2808-2813.
25. Yoshinaga SK, Zhang M, Pistillo J, et al. Characterization of a new human B7-related protein: B7RP-1 is the ligand to the co-stimulatory protein ICOS. Int Immunol 2000; 12:1439-1447.
26. Aicher A, Hayden-Ledbetter M, Brady WA, et al. Characterization of human inducible costimulator ligand expression and function. J Immunol 2000; 164:4689-4696.
27. Ling V, Wu PW, Miyashiro JS, et al. Differential expression of inducible costimulator-ligand splice variants: lymphoid regulation of mouse GL50-B and human GL50 molecules. J Immunol 2001; 166:7300-7308.
28. Wahl P, Schoop R, Bilic G, et al. Renal tubular epithelial expression of the costimulatory molecule B7RP-1 (Inducible costimulator ligand). J Am Soc Nephrol 2002; 13:1517-1526.
29. Swallow MM, Wallin JJ, Sha WC. B7h, a novel costimulatory homologue of B7.1 and B7.2, is induced by TNF-α. Immunity 1999; 11:423-432.
30. Richter G, Hayden-Ledbetter M, Irgang M, et al. Tumor necrosis factor-alpha regulates the expression of inducible costimulator receptor ligand on CD34(+) progenitor cells during differentiation into antigen presenting cells. J Biol Chem 2001; 276:45686-45693.
31. Hong Y, Zhou W, Li K, Sacks SH. Triptolide is a potent suppressant of C3, CD40 and B7h expression in activated human proximal tubular epithelial cells. Kidney Int 2002; 62:1291-1300.
32. Dong C, Juedes AE, Temann UA, et al. ICOS co-stimulatory receptor is essential for T-cell activation and function. Nature 2001; 409:97-101.
33. Tafuri A, Shahinian A, Bladt F, et al. ICOS is essential for effective T-helper-cell responses. Nature 2001; 409:105-109.
34. Dong C, Temann UA, Flavell RA. Cutting edge: critical role of inducible costimulator in germinal center reactions. J Immunol 2001; 166:3659-3662.
35. -/- mouse model. The paper provides a thorough workup regarding lymphoid organs, lymphocyte subclasses, basal and stimulated antibody reponses to various antigenic challenges.
36. -/- phenotype but contradicts the study of Wong et al. [35] in several aspects.
37. -/- mouse model.
38. Witsch E, Peiser M, Hutloff A, et al. ICOS and CD28 reversely regulate IL-10 on re-activation of human effector T cells with mature dendritic cells. Eur J Immunol 2002; 32:2680-2686. The authors show that ICOS is only fully expressed in later phases of T cell activation. Their observations suggest a hierarchy of costimulation, with a primary role of CD28 in the initial phase of antigen contact, and a significant involvement of ICOS in the effector phase of an immune reaction.
39. high T cells are exclusively linked to the antiinflammatory cytokine IL-10. Thus ICOS cell surface density serves as a regulatory mechanism for the release of different cytokines.
40. Greenwald RJ, McAdam AJ, Van der Woude D, et al. Cutting edge: inducible costimulator protein regulates both Th1 and Th2 responses to cutaneous leishmaniasis. J Immunol 2002; 168:991-995. ICOS deficiency abrogates the IgE response, but also affects Th1 as well as Th2 response to leishmaniasis.
41. Mittrücker HW, Kursar M, Köhler A, et al. Inducible costimulator protein controls the protective T cell response against Listeria monocytogenes. J Immunol 2002; 169:5813-5817. The only model in which the CD8 response is affected by blocking ICOS costimulation causing an increased susceptibility to Listerial infection.
42. Villegas EN, Lieberman LA, Mason N, et al. A role for inducible costimulator protein in the CD28-independent mechanism of resistance to Toxoplasma gondii. J Immunol 2002; 169:937-943. The Toxoplasma infection model demonstrates that many functions of ICOS can be compensated for by CD28 and vice versa.
43. -/- versus wildtype mice, and the lack of any difference in the CTL response in the absence of ICOS.
44. + T cells can express Th0, Th1 as well as Th2 cytokines, depending on the environment.
45. Gonzalo JA, Delaney T, Corcoran J, et al. Cutting edge: the related molecules CD28 and inducible costimulator deliver both unique and complementary signals required for optimal T cell activation. J Immunol 2001; 166:1-5.
46. Kopf M, Coyle AJ, Schmitz N, et al. Inducible costimulator protein (ICOS) controls T helper cell subset polarization after virus and parasite infection. J Exp Med 2000; 192:53-61.
47. Gonzalo JA, Tian J, Delaney T, et al. ICOS is critical for T helper cell-mediated lung mucosal inflammatory responses. Nat Immunol 2001; 2:597-604.
48. Tescubia AG, Subudhi S, Rother RP, et al. Inducible costimulator regulates Th2-mediated inflammation, but not Th2 differentiation, in a model of allergic airway disease. J Immunol 2001; 167:1996-2003.
49. Akbari O, Freeman GJ, Meyer EH, et al. Antigen-specific regulatory T cells develop via the ICOS-ICOS-ligand pathway and inhibit allergen-induced airway hyperreactivity. Nat Med 2002; 8:1024-1032. This paper claims to induce regulatory T cell development after respiratory exposure to allergen (ovalbumin) in the presence of IL-10 producing mature pulmonary dendritic cells. The authors provide evidence that these cells ameloriated ovalbumin induced asthma IL-10 and ICOS dependent pathway.
50. Wiley RE, Goncharova S, Shea T, et al. Evaluation of inducible costimulator/ B7-related protein-1 as a therapeutic target in a murine model of allergic airway inflammation. Am J Respir Cell Mol Biol 2003; 28:722-730. This report contradicts the previous findings that ICOS blockade is beneficial for asthma per se. The authors demonstrated that ICOS blockade during acute ovalbumin exposure ameliorated, but during ovalbumin recall exacerbated allergic asthma.
51. Rottmann JB, Smith T, Tonra JR, et al. The costimulatory molecule ICOS plays an important role in the immunopathogenesis of EAE. Nat Immunol 2001; 2:605-611.
52. Matsui Y, Okamoto H, Inobe M, et al. Adenovirus-mediated gene transfer of ICOSIg fusion protein ameliorates ongoing experimental autoimmune myocarditis. Hum Gene Ther 2003; 14:521-532. This study provides evidence that blockade of ICOS is beneficial for ongoing autoimmune myocarditis.
53. Futamatsu, H, Suzuki J, Kosuge H, et al. Attenuation of experimental autoimmune myocarditis by blocking activated T cells through inducible costimulatory molecule pathway. Cardiovasc Res 2003; 59:95-104. The study of experimental autoimmune myocarditis in rats nicely demonstrates the impact of blocking ICOS as well as ICOS-L on the effector, but not the priming phase of the immune response, making it a potential therapeutic target in autoimmune myocarditis.
54. Wiendl H, Mitsdoerffer M, Schneider D, et al. Muscle fibres and cultured muscle cells express the B7.1/2-related inducible co-stimulatory molecule, ICOSL: implications for the pathogenesis of inflammatory myopathies. Brain 2003; 126:1026-1035.
55. Nurieva RI, Treuting P, Duong J, et al. Inducible costimulator is essential for collagen-induced arthritis. J Clin Invest 2003; 111:701-706. The authors demonstrate the essential role of ICOS costimulation in collagen induced arthritis possibly due to induction of IL-17.
56. Iwai H, Kozono Y, Hirose S, et al. Amelioration of collagen-induced arthritis by blockade of inducible costimulator-B7 homologous protein costimulation. J Immunol 2002; 169:4332-4339. Antibody blockade confirms finding in knockout mouse and therefore suggests therapeutic principal for autoimmune disease.
57. Tada Y, Nagasawa K, Ho A, et al. CD28-deficient mice are highly resistant to collagen-induced arthritis. J Immunol 1999; 162:203-208.
58. Fossiez F, Djossou O, Chomarat P, et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med 1996; 183:2593-2603.
59. Okamoto T, Saito S, Yamanaka H, et al. Expression and function of the costimulator H4/ICOS on activated T cells of patients with rheumatoid arthritis. J Rheumatol 2003; 30:1157-1163. Detection of increased ICOS and ICOS-L in synovial tissue in humans with rheumatoid arthritis.
60. + T cells.
61. Özkaynak E, Gao W, Shemmeri N, et al. Importance of ICOS-B7RP-1 costimulation in acute and chronic allograft rejection. Nat Immunol 2001; 2:591-596.
62. Kosuge H, Suzuki JI, Gotoh R, et al. Induction of immunologic tolerance to cardiac allograft by simultaneous blockade of inducible co-stimulator and cytotoxic T-lymphocyte antigen 4 pathway. Transplantation 2003; 75:1374-1380. This group induced a long-term, allograft specific tolerance in C3H/He mice transplanted with hearts from BALB/c mice by blockade of both ICOS and CTLA-4 costimulatory molecules.
63. Salama AD, Yuan X, Nayer A, et al. Interaction between ICOS-B7RP1 and B7-CD28 costimulatory pathways in alloimmune responses in vivo. Am J Transplant 2003; 3:390-395. This group studied the timing of ICOS blockade in a model of rat cardiac allotransplantation and found differences in graft survival comparing the blockade at the day of transplantation with 2 days following transplantation.
64. Guo L, Li XK, Funeshima N, et al. Prolonged survival in rat liver transplantation with mouse monoclonal antibody against an inducible costimulator (ICOS). Transplantation 2002; 73:1027-1032. This study of liver transplant survival in rats treated with an anti-ICOS antibody confirms the beneficial role of ICOS blockade in transplant rejection models.
65. Nakamura Y, Yasunami Y, Satoh M, et al. Acceptance of islet allografts in the liver of mice by blockade of an inducible costimulator. Transplantation 2003; 75:1115-1118.
66. Ogasawara K, Yoshinaga SK, Lanier LL. Inducible costimulator costimulates cytotoxic activity and IFN-γ production in activated murine NK cells. J Immunol 2002; 169:3676-3685. In this study, the role of ICOS in NK cell mediated cytotoxicity and cytokine production was assessed. To determine whether ICOS contributes to the elimination of tumors in vivo, tumor growth and the survival of mice injected with the tumor expressing ICOS-L were examined. So far this is the only paper demonstrating effects of ICOS costimulation in NK cell activity and its potential importance in tumor surveillance.
67. Ara G, Baher A, Storm N, et al. Potent activity of soluble B7RP-1-Fc in therapy of murine tumors in syngeneic hosts. Int J Cancer 2003; 103:501-507.